For decades, extracorporeal life support (ECLS) systems have relied on pumps designed for short-term cardiopulmonary bypass. In the past, occlusive roller pumps were the standard. They are being progressively replaced by centrifugal pumps and devices developed specifically for ECLS. However, the ideal pump for long-term bypass is yet to be created. One interesting alternative is the Rhône-Poulenc 06 pump that is a nonocclusive pressure-regulated blood pump developed in France in the 1970s. This pump is composed of a double-stage rotor with three rollers at each level. The raceway tubing is stretched on the roller and pump occlusivity depends on the tension of the chamber on the rotor. The pump is able to deliver physiological blood flow values without generating dangerous negative or positive pressures. The specific design of the chamber allows the pump to generate a pulsatile flow, inducing minimal blood trauma, and to act as a bubble trap, making it inherently safe. This pump has been used for cardiopulmonary bypass, extracorporeal lung support, and more specifically single-lumen single-cannula venovenous membrane oxygenation for neonates, left-heart or right-heart assist, and venovenous bypass during liver transplant. In conclusion, this old-fashion pump is perfectly adapted for any kind of short- or long-term bypass.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1525-1594.2012.01566.x | DOI Listing |
PLoS One
January 2025
French National Reference Center for Primary Immunodeficiencies (CEREDIH) and Pediatric Immunology, Hematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.
Background: Subcutaneous immunoglobulin (SCIg) replacement therapy is indicated for patients with hypogammaglobulinemia caused by primary (PID) and secondary immunodeficiencies (SID).
Objective: To compare healthcare resource utilization (HCRU) and related direct medical costs of patients in France treated with weekly conventional SCIg (cSCIg) vs monthly hyaluronidase-facilitated SCIg (fSCIg).
Methods: This retrospective study of Ig-naïve patients with PID or SID newly receiving a SCIg between 2016 and 2018, extracted from the French National Healthcare reimbursement database (SNDS), analyzed the SCIg-related HCRU and reimbursed costs generated from in-hospital (hospitalizations and SCIg doses) or at-home (nurse visits [NV] and pump provider visits [PPV], drug doses) SCIg administration.
ASAIO J
January 2025
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
The use of an alteplase (Activase) purge solution to address Impella ventricular assist device "thrombosis" or "purge system occlusion" has been mainly documented with earlier generation Impella devices (CP, 2.5, 5.0).
View Article and Find Full Text PDFProc Natl Acad Sci U S A
January 2025
Faculty of Technical Chemistry, Institute of Chemical Technologies and Analytics, Technische Universität Wien, Vienna 1060, Austria.
Atomic force microscopy-infrared spectroscopy (AFM-IR) is a photothermal scanning probe technique that combines nanoscale spatial resolution with the chemical analysis capability of mid-infrared spectroscopy. Using this hybrid technique, chemical identification down to the single molecule level has been demonstrated. However, the mechanism at the heart of AFM-IR, the transduction of local photothermal heating to cantilever deflection, is still not fully understood.
View Article and Find Full Text PDFChemMedChem
January 2025
University of Michigan Michigan Medicine, Internal Medicine, 2800 Plymouth Rd, NCRC 26-220S, 48109, Ann Arbor, UNITED STATES OF AMERICA.
A key molecular dysfunction in heart failure is the reduced activity of the cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) in cardiac muscle cells. Reactivating SERCA2a improves cardiac function in heart failure models, making it a validated target and an attractive therapeutic approach for heart failure therapy. However, finding small-molecule SERCA2a activators is challenging.
View Article and Find Full Text PDFJ Cardiovasc Dev Dis
January 2025
Department of Cardiac Surgery, Lankenau Heart Institute, Main Line Health, Wynnewood, PA 19096, USA.
Objectives: The impact of long-term complications after robotic hybrid coronary revascularization (HCR), including persistent angina, repeat revascularization, and myocardial infarction (MI), remains limited. This study aims to determine the risk factors for coronary events after robotic HCR and their time-varying effects on outcomes.
Methods: We identified all consecutive patients who underwent robotic HCR at our institution.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!